205 related articles for article (PubMed ID: 9724371)
1. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results.
Sugawara Y; Braun DK; Kison PV; Russo JE; Zasadny KR; Wahl RL
Eur J Nucl Med; 1998 Sep; 25(9):1238-43. PubMed ID: 9724371
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?
Basu S; Chryssikos T; Houseni M; Scot Malay D; Shah J; Zhuang H; Alavi A
Nucl Med Commun; 2007 Jun; 28(6):465-72. PubMed ID: 17460537
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes.
Mahfouz T; Miceli MH; Saghafifar F; Stroud S; Jones-Jackson L; Walker R; Grazziutti ML; Purnell G; Fassas A; Tricot G; Barlogie B; Anaissie E
J Clin Oncol; 2005 Nov; 23(31):7857-63. PubMed ID: 16204017
[TBL] [Abstract][Full Text] [Related]
6. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.
Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
Radiology; 1998 Mar; 206(3):749-54. PubMed ID: 9494496
[TBL] [Abstract][Full Text] [Related]
7. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection.
Chacko TK; Zhuang H; Nakhoda KZ; Moussavian B; Alavi A
Nucl Med Commun; 2003 Jun; 24(6):615-24. PubMed ID: 12766596
[TBL] [Abstract][Full Text] [Related]
8. Infection imaging using whole-body FDG-PET.
Stumpe KD; Dazzi H; Schaffner A; von Schulthess GK
Eur J Nucl Med; 2000 Jul; 27(7):822-32. PubMed ID: 10952494
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
10. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases.
Kälicke T; Schmitz A; Risse JH; Arens S; Keller E; Hansis M; Schmitt O; Biersack HJ; Grünwald F
Eur J Nucl Med; 2000 May; 27(5):524-8. PubMed ID: 10853807
[TBL] [Abstract][Full Text] [Related]
12. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
13. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging.
Zhuang H; Duarte PS; Pourdehand M; Shnier D; Alavi A
Clin Nucl Med; 2000 Apr; 25(4):281-4. PubMed ID: 10750968
[TBL] [Abstract][Full Text] [Related]
14. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.
Nakamoto Y; Eisbruch A; Achtyes ED; Sugawara Y; Reynolds KR; Johnston CM; Wahl RL
Gynecol Oncol; 2002 Feb; 84(2):289-95. PubMed ID: 11812089
[TBL] [Abstract][Full Text] [Related]
16. The diabetic foot: initial experience with 18F-FDG PET/CT.
Keidar Z; Militianu D; Melamed E; Bar-Shalom R; Israel O
J Nucl Med; 2005 Mar; 46(3):444-9. PubMed ID: 15750157
[TBL] [Abstract][Full Text] [Related]
17. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
[TBL] [Abstract][Full Text] [Related]
18. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.
Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
J Nucl Med; 1998 Dec; 39(12):2145-52. PubMed ID: 9867159
[TBL] [Abstract][Full Text] [Related]
19. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
Miyauchi T; Wahl RL
Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
[TBL] [Abstract][Full Text] [Related]
20. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
